LiveAction, Inc – Trademark Portfolio
Entity Type: 03
LiveAction, Inc holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 15 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include LIVENX, OMNIPEEK, LIVEACTION, and OMNIPLIANCE. The owner is based in Campbell, CA.
901 Campisi Way
Suite 222
Campbell, CA 95008
Showing of trademarks Trademarks
Trademark Classifications
LiveAction, Inc's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does LiveAction, Inc have?
LiveAction, Inc has 15 U.S. trademarks filed with the USPTO. Of these, 4 registered, 6 abandoned, 5 cancelled.
What trademark classes does LiveAction, Inc file in?
LiveAction, Inc files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are LiveAction, Inc's most well-known trademarks?
LiveAction, Inc's registered trademark portfolio includes well-known marks such as LIVENX, OMNIPEEK, LIVEACTION, and OMNIPLIANCE. These are among 4 currently registered trademarks in the portfolio.
What is LiveAction, Inc's trademark registration success rate?
LiveAction, Inc has a 27% trademark registration rate, with 4 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.